Compare CAAS & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | CVRX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.9M | 139.8M |
| IPO Year | 2025 | 2021 |
| Metric | CAAS | CVRX |
|---|---|---|
| Price | $4.70 | $3.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 26.0K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $4.00 | $2.20 |
| 52 Week High | $5.15 | $11.30 |
| Indicator | CAAS | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 36.00 |
| Support Level | $4.38 | N/A |
| Resistance Level | $4.91 | $6.06 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 53.09 | 24.21 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.